We are live on ! Find out more
PSTX

Poseida Therapeutics, Inc. Common Stock
PSTX

Delisted

PSTX was delisted on the 7th of January, 2025.

Back to rankings

94 hedge funds and large institutions have $78.4M invested in Poseida Therapeutics, Inc. Common Stock in 2023 Q2 according to their latest regulatory filings, with 27 funds opening new positions, 35 increasing their positions, 17 reducing their positions, and 34 closing their positions.

New
Increased
Maintained
Reduced
Closed

388% more call options, than puts

Call options by funds: $195K | Put options by funds: $40K

106% more repeat investments, than reductions

Existing positions increased: 35 | Existing positions reduced: 17

7% less funds holding

Funds holding: 101 → 94 (-7)

21% less first-time investments, than exits

New positions opened: 27 | Existing positions closed: 34

42% less capital invested

Capital invested by funds: $136M → $78.4M (-$57.6M)

100% less funds holding in top 10

Funds holding in top 10: 2 → 0 (-2)

Holders
94
Holders Change
-7
Holders Change %
-6.93%
% of All Funds
1.48%
Holding in Top 10
–
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-100%
% of All Funds
–
New
27
Increased
35
Reduced
17
Closed
34
Calls
$195K
Puts
$40K
Net Calls
+$155K
Net Calls Change
+$3K

Top Buyers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
+$8.42M
2
State Street
State Street
Massachusetts
+$2.26M
3
Geode Capital Management
Geode Capital Management
Massachusetts
+$1.84M
4
William Blair & Company
William Blair & Company
Illinois
+$1.37M
5
Northern Trust
Northern Trust
Illinois
+$1.04M

Top Sellers

Rank Fund Capital Flow
1
EC
EcoR1 Capital
California
-$5.04M
2
PBA
Paradigm Biocapital Advisors
New York
-$3.3M
3
CAM
Cormorant Asset Management
Massachusetts
-$3.08M
4
LCM
Laurion Capital Management
New York
-$1.68M
5
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$1.56M
Name Holding Trade Value Shares
Change 		Change in
Stake
Fidelity Investments
1
Fidelity Investments
Massachusetts
$22.9M +$95.2K +37,251 +0.3%
PCM
2
Pentwater Capital Management
Florida
$10.5M – – –
BlackRock
3
BlackRock
New York
$9.12M +$8.42M +3,294,442 +174%
SCM
4
Silverarc Capital Management
Massachusetts
$5.18M +$656K +256,647 +10%
Vanguard Group
5
Vanguard Group
Pennsylvania
$4.56M +$589K +230,447 +10%
Geode Capital Management
6
Geode Capital Management
Massachusetts
$2.16M +$1.84M +718,477 +142%
Millennium Management
7
Millennium Management
New York
$2.01M +$431K +168,739 +17%
State Street
8
State Street
Massachusetts
$1.97M +$2.26M +884,288 +377%
Acadian Asset Management
9
Acadian Asset Management
Massachusetts
$1.95M +$255K +99,989 +10%
ACM
10
Aisling Capital Management
New York
$1.84M – – –
Dimensional Fund Advisors
11
Dimensional Fund Advisors
Texas
$1.23M -$137K -53,599 -7%
EC
12
EcoR1 Capital
California
$1.19M -$5.04M -1,973,704 -74%
William Blair & Company
13
William Blair & Company
Illinois
$1M +$1.37M +534,397 +1,556%
Morgan Stanley
14
Morgan Stanley
New York
$978K +$189K +74,090 +15%
Renaissance Technologies
15
Renaissance Technologies
New York
$950K -$161K -63,176 -10%
Northern Trust
16
Northern Trust
Illinois
$898K +$1.04M +406,192 +391%
Two Sigma Investments
17
Two Sigma Investments
New York
$762K -$123K -48,200 -10%
Charles Schwab
18
Charles Schwab
California
$756K +$431K +168,830 +65%
N
19
Nuveen
North Carolina
$643K +$933K +365,191 New
Bank of America
20
Bank of America
North Carolina
$584K +$204K +79,878 +32%
ASN
21
Advisory Services Network
Georgia
$453K – – –
Goldman Sachs
22
Goldman Sachs
New York
$439K -$112K -43,770 -15%
Mirae Asset Global Investments
23
Mirae Asset Global Investments
South Korea
$415K +$603K +235,969 New
XT
24
XTX Topco
Cayman Islands
$411K +$210K +82,404 +55%
Squarepoint
25
Squarepoint
New York
$405K +$149K +58,155 +34%
1
2 3 4 5

PSTX Hedge Fund Activity: Q2 2023 in Review

94 of the 6,370 institutional investors tracked by Wall St. Rank reported a position in Poseida Therapeutics, Inc. Common Stock (PSTX) for Q2 2023, worth a combined $78.4M — down 42% from $136M a quarter earlier.

Sellers outnumbered buyers: 34 funds closed out of PSTX and 27 opened new positions — a net loss of 7 holders — while 17 trimmed existing stakes and 35 added.

The largest buyer was BlackRock, adding an estimated $8.42M. The largest seller was EcoR1 Capital, cutting an estimated $5.04M.

  • 94 institutional investors held Poseida Therapeutics, Inc. Common Stock (PSTX) as of Q2 2023, down from 101 in Q1 2023.
  • Funds reported $78.4M of Poseida Therapeutics, Inc. Common Stock stock for Q2 2023, down 42% quarter-over-quarter.
  • 27 funds opened new Poseida Therapeutics, Inc. Common Stock positions in Q2 2023 and 34 closed out, a net change of -7 holders.
  • The largest Poseida Therapeutics, Inc. Common Stock buyer in Q2 2023 was BlackRock, an estimated $8.42M added.
  • The largest Poseida Therapeutics, Inc. Common Stock seller in Q2 2023 was EcoR1 Capital, an estimated $5.04M sold.

Based on aggregated 13F filings for Q2 2023.